Stocks and Investing Stocks and Investing
Fri, July 12, 2024

Chris Shibutani Maintained (AMLX) at Hold with Increased Target to $4 on, Jul 12th, 2024


Published on 2024-10-28 12:24:56 - WOPRAI, Chris Shibutani
  Print publication without navigation


Chris Shibutani of Goldman Sachs, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Hold with Increased Target from $3 to $4 on, Jul 12th, 2024.

Chris has made no other calls on AMLX in the last 4 months.



There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 2 agree with Chris's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Graig Suvannavejh of "Mizuho" Maintained at Hold with Decreased Target to $3 on, Tuesday, May 14th, 2024
  • Joel Beatty of "Baird" Maintained at Hold with Decreased Target to $3 on, Thursday, April 11th, 2024


This is the rating of the analyst that currently disagrees with Chris


  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $8 on, Wednesday, July 10th, 2024

Contributing Sources